Project Grant R43CA302117
Award Date
7/1/25
Completion Date
12/31/25
Dollars Obligated
$317K
Federal Agency
National Cancer Institute
Federal Grant Program
93.394
Assistance Type
Project Grant
Place of Performance
North Carolina, USA
Similar Awards
The National Cancer Institute (NCI) awarded a $962,560 Project Grant (CFDA 93.394 - Cancer Detection and Diagnosis Research) to Basic Health International Inc., a non-profit organization in Pittsburgh, Pennsylvania. The grant aims to modify and clinically validate the IRISTM device, a handheld thermal ablation device and digital colposcope designed for cervical cancer screening and treatment in low- and middle-income countries (LMIC). The key goals of the project are to: 1) Modify the IRISTM...
The National Cancer Institute (NCI) awarded a $400,000 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to Argosmd, Inc. to develop a low-cost, non-invasive "Mini-Reflectance Confocal Microscope (Mini-RCM)" device for aiding skin cancer diagnosis and treatment. The goal is to create a portable, fast-imaging microscopy tool that can improve upon existing Reflectance Confocal Microscopy (RCM) technology, which is currently limited in adoption due to...
The National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), awarded a $1,172,978 Phase II Small Business Innovation Research (SBIR) grant to Ananya Health Inc. to develop a portable, battery-powered, closed-loop cryotherapy system for the treatment of cervical precancerous lesions in low- and middle-income countries (LMICs). The key objectives of this 2-year project are to: 1) finalize the system design and verify it meets all requirements...
This $399,499 Project Grant award from the National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), supports the development of Liquid Biotech's TELOMESCAN circulating tumor cell (CTC) assay for monitoring non-small cell lung cancer (NSCLC) patients undergoing radiation and immunotherapy. The key products and services to be delivered through this funding include: 1) Developing a clinical prototype of the TELOMESCAN assay with automated analysis to...
The National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) awarded a $399,998 Project Grant to Darwin Biosciences, Inc. to develop a low-cost, handheld, and non-invasive lung cancer screening device for use in low-resource settings. The goal of this 1-year Phase I project is to adapt Darwin Biosciences' existing platform, which was developed under a separate DoD contract, to detect circulating tumor DNA biomarkers for non-small cell lung cancer using saliva and...
This Project Grant award from the National Cancer Institute's Cancer Detection and Diagnosis Research program (CFDA 93.394) provides $978,154 to Surgivance Inc. to further develop their digital pathology "laboratory-in-a-box" solution that rapidly produces and analyzes high-resolution, 3D digital pathology images for skin cancer detection at the point of care. The specific goals are to: 1) refine the AI algorithms for improved detection of basal and squamous cell carcinomas, 2) develop...
This Project Grant award from the National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), will support the development and clinical validation of an Optical Coherence Tomography (OCT) system and two specialized OCT imaging probes to enhance colorectal cancer screening. The $1,471,777 award to The General Hospital Corporation (doing business as Massachusetts General Hospital) aims to create an OCT system that can obtain 3D microscopic images of...
The National Cancer Institute (NCI) awarded a $671,072 Project Grant under CFDA 93.394 (Cancer Detection and Diagnosis Research) to the University of Washington (UW) to develop a novel ultra-miniaturized device termed "Picoliter Thin-Layer Chromatography (PTLC)" for high-throughput and sensitive analysis of lipid signaling in single cells from patient samples. This 5-year award, effective April 1, 2025, will leverage micro- and nano-fabrication techniques to create an easy-to-use,...
This Cooperative Agreement award from the National Cancer Institute's Cancer Detection and Diagnosis Research program (CFDA 93.394) provides $957,152 to GE Medical Systems Information Technologies, Inc. to develop and deploy an affordable automated point-of-care (POC) telecytology platform for oral cancer screening in India. The platform aims to reliably establish oral cancer diagnosis in community settings and enable immediate referral for treatment. Key project goals include creating a...
This $353,204 Project Grant awarded by the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396) supports the development of a novel technology called Cell-MAPP by Pumpkinseed Technologies Inc., a for-profit company located in Palo Alto, California. The goal of this Phase I Small Business Innovation Research (SBIR) project is to demonstrate and advance Cell-MAPP, a live-cell monitoring system that enables continuous, high-throughput analysis of T cell states...